NEXTBio Capital Management LP's Q1 2026 13F: 1 new position
Form 13F-HR for the quarter ended Mar 31, 2026 · filed May 14, 2026 · 24 reported positions · accession 0001172661-26-001957
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | COMPASS PATHWAYS PLC (CMPS) | 3.0% | 5.2% | +2.1 pts | +1.27M sh | +169% |
| Increased | RHYTHM PHARMACEUTICALS INC (RYTM) | 4.2% | 5.1% | +0.8 pts | +58,492 sh | +87% |
| Increased | TERNS PHARMACEUTICALS INC (TERN) | 13.1% | 14.8% | +1.7 pts | +53,344 sh | +10% |
| Increased | ZENAS BIOPHARMA INC (ZBIO) | 6.9% | 3.9% | −3.0 pts | +105K sh | +33% |
| Increased | STRUCTURE THERAPEUTICS INC (GPCR) | 3.9% | 3.0% | −0.9 pts | +38,796 sh | +41% |
| New | SUMMIT THERAPEUTICS INC (SMMT) | — | 0.8% | +0.8 pts | +89,717 sh | new |
| Reduced | COMPASS THERAPEUTICS INC (CMPX) | 3.5% | 2.1% | −1.4 pts | −266K sh | −24% |
| Increased | COGENT BIOSCIENCES INC (COGT) | 2.0% | 2.3% | +0.3 pts | +35,369 sh | +37% |
| Reduced | ORIC PHARMACEUTICALS INC (ORIC) | 3.0% | 3.1% | +0.1 pts | −92,101 sh | −15% |
| Reduced | EVOMMUNE INC (EVMN) | 2.3% | 2.0% | −0.3 pts | −44,223 sh | −19% |
| Increased | DISC MEDICINE INC (IRON) | 2.0% | 1.6% | −0.4 pts | +9,877 sh | +23% |
| Increased | ZAI LAB LTD (ZLAB) | 1.7% | 1.6% | −0.1 pts | +20,000 sh | +12% |
| Increased | INVENTIVA SA (IVA) | 3.5% | 3.4% | −0.1 pts | +34,783 sh | +3% |
| Reduced | XENON PHARMACEUTICALS INC (XENE) | 4.8% | 4.9% | +0.1 pts | −479 sh | 0% |
| Reduced | VAXCYTE INC (PCVX) | 2.6% | 2.6% | 0.0 pts | −262 sh | 0% |
| Reduced | OCULIS HOLDING AG (OCS) | 1.8% | 1.8% | +0.1 pts | −158 sh | 0% |
| Reduced | VERASTEM INC (VSTM) | 5.9% | 3.2% | −2.7 pts | −530 sh | 0% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 71.0% of the equity book
Changes in the top 10 this quarter: CMPS entered · IVA entered · VSTM left · GPCR left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | TERNS PHARMACEUTICALS INC (TERN) | 13.1% | 14.8% | |
| 2 | PROTAGONIST THERAPEUTICS INC (PTGX) | 11.8% | 11.2% | |
| 3 | SHATTUCK LABS INC (STTK) | 6.7% | 9.4% | |
| 4 | VOR BIOPHARMA INC (VOR) | 7.7% | 8.3% | |
| 5 | COMPASS PATHWAYS PLC (CMPS) | 3.0% | 5.2% | Entered the top 10 |
| 6 | RHYTHM PHARMACEUTICALS INC (RYTM) | 4.2% | 5.1% | |
| 7 | XENON PHARMACEUTICALS INC (XENE) | 4.8% | 4.9% | |
| 8 | PALVELLA THERAPEUTICS INC NE (PVLA) | 5.1% | 4.8% | |
| 9 | ZENAS BIOPHARMA INC (ZBIO) | 6.9% | 3.9% | |
| 10 | INVENTIVA SA (IVA) | 3.5% | 3.4% | Entered the top 10 |
| — | VERASTEM INC (VSTM) | 5.9% | 3.2% | Left the top 10 |
| — | STRUCTURE THERAPEUTICS INC (GPCR) | 3.9% | 3.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).